StockNews.AI
OTLK
StockNews.AI
2 days

Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)

1. OTLK will present at EURETINA Innovation Spotlight on September 3, 2025. 2. CEO Bob Jahr will discuss optimizing treatment for retinal diseases. 3. LYTENAVA™ is the first ophthalmic bevacizumab formulation approved in Europe. 4. ONS-5010 is investigational in the U.S. but has potential for approval. 5. Commercial launch in Germany and UK indicates positive market entry.

3m saved
Insight
Article

FAQ

Why Bullish?

The approval of LYTENAVA™ in Europe could enhance investor confidence, similar to previous successful launch cases in biotech where regulatory approvals led to stock price surges.

How important is it?

The article highlights a key industry event for OTLK, which could impact market perceptions and investor sentiment positively.

Why Short Term?

The upcoming presentation at an industry event can create immediate investor interest and market activity, particularly if new data or insights are shared.

Related Companies

BMYREGNNVDA
September 03, 2025 08:35 ET  | Source: Outlook Therapeutics, Inc. ISELIN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will present at the EURETINA Innovation Spotlight being held as part of the 25th EURETINA Congress on September 3, 2025 in Le Palais des Congrès, Paris. Details for the presentations are as follows: Session: VEGF Related and Other Retinal Indications Title: Optimising the treatment of retinal diseasePresenter: Bob Jahr, Chief Executive Officer of Outlook TherapeuticsDate and Time: Wednesday, September 3, 2025, 16:10 PM CEST / 10:10 AM EDT For more information about this event, please visit EIS 2025. About Outlook Therapeutics, Inc. Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) to optimize the standard of care for bevacizumab for the treatment of retina diseases. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK as a treatment for wet AMD. In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD. Investor Inquiries:Jenene ThomasChief Executive OfficerJTC Team, LLCT: 908.824.0775OTLK@jtcir.com

Related News